| adrenergic receptor, beta 3 |
ALPHA-ERGOCRYPTINE |
Adrenergic beta3 |
73% |
2.496uM |
1.872uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 5B |
BERBERINE CHLORIDE |
Serotonin 5-HT4 |
73% |
2.222uM |
.37uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 4 |
BERBERINE CHLORIDE |
Serotonin 5-HT4 |
73% |
2.222uM |
.37uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| ATPase, Na+/K+ transporting, alpha 3 polypeptide |
SODIUM ORTHOVANADATE |
ATPase, Na+/K+ |
72% |
1.853uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, alpha 2 polypeptide |
SODIUM ORTHOVANADATE |
ATPase, Na+/K+ |
72% |
1.853uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, alpha 1 polypeptide |
SODIUM ORTHOVANADATE |
ATPase, Na+/K+ |
72% |
1.853uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, beta 1 polypeptide |
SODIUM ORTHOVANADATE |
ATPase, Na+/K+ |
72% |
1.853uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, beta 3 polypeptide |
SODIUM ORTHOVANADATE |
ATPase, Na+/K+ |
72% |
1.853uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, beta 2 polypeptide |
SODIUM ORTHOVANADATE |
ATPase, Na+/K+ |
72% |
1.853uM |
NoneNone |
View
|
| ATPase, (Na+)/K+ transporting, beta 4 polypeptide |
SODIUM ORTHOVANADATE |
ATPase, Na+/K+ |
72% |
1.853uM |
NoneNone |
View
|
| matrix metallopeptidase 9 |
BUSULFAN |
Protease, Matrix Metalloprotease-9 (MMP-9) |
72% |
5.215uM |
NoneNone |
View
|
| matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) |
BUSULFAN |
Protease, Matrix Metalloprotease-9 (MMP-9) |
72% |
5.215uM |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
PROMETHAZINE |
Adrenergic, Norepinephrine Transporter |
72% |
4.238uM |
4.203uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
CETYLPYRIDINIUM BROMIDE |
Serotonin 5-HT2B |
72% |
5.69uM |
3.621uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
PHENTOLAMINE |
Serotonin 5-HT2B |
72% |
3.807uM |
2.422uM |
View
|
| A3 adenosine receptor |
NISOLDIPINE |
Adenosine A3 |
72% |
7.12uM |
4.024uM |
View
|
| adrenergic receptor, beta 3 |
ASTEMIZOLE |
Adrenergic beta3 |
72% |
8.06uM |
6.045uM |
View
|
| lymphocyte protein tyrosine kinase (mapped) |
ASTEMIZOLE |
Protein Tyrosine Kinase, Lck |
72% |
19.92uM |
NoneNone |
View
|
| 5-hydroxytryptamine receptor 6 |
CLOMIPHENE |
Serotonin 5-HT6 |
72% |
1.522uM |
.707uM |
View
|
| adrenergic receptor, alpha 1b |
CLOMIPHENE |
Adrenergic alpha1B |
72% |
4.569uM |
2.529uM |
View
|
| cholinergic receptor, muscarinic 4 |
DROPERIDOL |
Muscarinic M4 |
72% |
3.849uM |
.537uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
DROPERIDOL |
Serotonin 5-HT2B |
72% |
1.342uM |
.854uM |
View
|
| sodium channel, voltage-gated, type I, beta |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type II, beta |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, nonvoltage-gated 1 beta |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, nonvoltage-gated 1, delta |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type X, alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage gated, type VIII, alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| adrenergic receptor, alpha 2a |
YOHIMBINE |
Imidazoline I2, Central |
72% |
.157uM |
.105uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
YOHIMBINE |
Imidazoline I2, Central |
72% |
.157uM |
.105uM |
View
|
| adrenergic receptor, beta 1 |
TAMOXIFEN |
Adrenergic beta1 |
72% |
17.289uM |
9.984uM |
View
|
| adrenergic, beta-1-, receptor |
TAMOXIFEN |
Adrenergic beta1 |
72% |
17.289uM |
9.984uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
CLOMIPRAMINE |
Dopamine Transporter |
72% |
2.746uM |
2.182uM |
View
|
| adrenergic receptor, alpha 2b |
METHAPYRILENE |
Adrenergic alpha2B |
72% |
3.318uM |
1.515uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2A |
TETRACAINE |
Serotonin 5-HT2A |
72% |
3.415uM |
.976uM |
View
|
| cholinergic receptor, muscarinic 3 |
FLUOXETINE |
Muscarinic M3 |
72% |
3.595uM |
.762uM |
View
|
| Sigma-2 Receptor |
FLUPHENAZINE |
Sigma2 |
72% |
.158uM |
.097uM |
View
|
| Cytochrom P450-1A2 monooxygenase |
SULINDAC SULFIDE |
CYP450-1A2 Inhibition |
72% |
2uM |
NoneNone |
View
|
| Cytochrom P450-1A2 monooxygenase |
NABUMETONE |
CYP450-1A2 Inhibition |
72% |
5uM |
NoneNone |
View
|
| opioid receptor, sigma 1 |
R-(+)-PROPRANOLOL |
Sigma1 |
72% |
3.974uM |
1.67uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
HALOPERIDOL |
Serotonin Transporter |
72% |
3.386uM |
1.799uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
R-(+)-PROPRANOLOL |
Serotonin 5-HT1A |
72% |
4.88uM |
2.789uM |
View
|
| dopamine receptor D1A |
LYSERGOL |
Dopamine D1 |
72% |
2.908uM |
1.454uM |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
LYSERGOL |
Adrenergic alpha1D |
72% |
1.128uM |
.554uM |
View
|
| adrenergic receptor, alpha 2a |
METHYSERGIDE |
Imidazoline I2, Central |
72% |
2.519uM |
1.68uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
METHYSERGIDE |
Imidazoline I2, Central |
72% |
2.519uM |
1.68uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 1 |
CHLORPROMAZINE |
Potassium Channel HERG |
72% |
5.8275uM |
4.7743uM |
View
|
| potassium voltage-gated channel, subfamily H, member 8 |
VERAPAMIL |
Potassium Channel HERG |
72% |
NoneNone |
NoneNone |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 6 |
VERAPAMIL |
Potassium Channel HERG |
72% |
NoneNone |
NoneNone |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 7 |
VERAPAMIL |
Potassium Channel HERG |
72% |
NoneNone |
NoneNone |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 2 |
VERAPAMIL |
Potassium Channel HERG |
72% |
NoneNone |
NoneNone |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 5 |
VERAPAMIL |
Potassium Channel HERG |
72% |
NoneNone |
NoneNone |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 3 |
VERAPAMIL |
Potassium Channel HERG |
72% |
NoneNone |
NoneNone |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 4 |
VERAPAMIL |
Potassium Channel HERG |
72% |
NoneNone |
NoneNone |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 1 |
VERAPAMIL |
Potassium Channel HERG |
72% |
NoneNone |
NoneNone |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 1 |
VERAPAMIL |
Potassium Channel HERG |
72% |
NoneNone |
NoneNone |
View
|
| androgen receptor |
ZINC CHLORIDE |
Testosterone |
72% |
6.5086uM |
4.3391uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
HEXACHLOROPHENE |
Serotonin 5-HT2B |
72% |
5.6947uM |
3.6239uM |
View
|
| mitogen activated protein kinase 14 |
NAFENOPIN |
Protein Serine/Threonine Kinase, p38alpha |
72% |
3.7405uM |
NoneNone |
View
|
| mitogen-activated protein kinase 14 |
NAFENOPIN |
Protein Serine/Threonine Kinase, p38alpha |
72% |
3.7405uM |
NoneNone |
View
|
| cholinergic receptor, muscarinic 1 |
SULOCTIDIL |
Muscarinic M1 |
72% |
4.505uM |
1.085uM |
View
|
| Cytochrom P450-1A2 monooxygenase |
THIORIDAZINE |
CYP450-1A2 Inhibition |
72% |
9.3323uM |
NoneNone |
View
|
| Sigma-2 Receptor |
TOLPERISONE |
Sigma2 |
72% |
3.357uM |
2.066uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
FLUNARIZINE |
Serotonin 5-HT1A |
72% |
4.281uM |
2.446uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
LEVOBUNOLOL |
Serotonin 5-HT1A |
72% |
2.901uM |
1.658uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
CYCLIZINE |
Calcium Channel Type L, Phenylalkylamine |
72% |
4.644uM |
4.515uM |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
RWJ-68354 |
CYP450-3A4 Inhibition |
72% |
1uM |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
TRIHEXYPHENIDYL |
CYP450-2D6 Inhibition |
72% |
2.4498uM |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
NALOXONE |
CYP450-2D6 Inhibition |
72% |
2uM |
NoneNone |
View
|
| Cytochrom P450-2C19 monooxygenase |
SPIRONOLACTONE |
CYP450-2C19 Inhibition |
72% |
3uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
BITHIONOL |
Serotonin 5-HT2C |
72% |
8.78uM |
4.599uM |
View
|
| dopamine receptor D3 |
DIPHENIDOL |
Dopamine D3 |
72% |
2.311uM |
.785uM |
View
|
| dopamine receptor D3 |
DOBUTAMINE |
Dopamine D3 |
72% |
4.985uM |
1.693uM |
View
|
| adrenergic receptor, alpha 2b |
CLOSANTEL |
Adrenergic alpha2C |
72% |
7.1uM |
1uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
CLOSANTEL |
Adrenergic alpha2C |
72% |
7.1uM |
1uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
CLOSANTEL |
Dopamine Transporter |
72% |
4.8uM |
3.8uM |
View
|
| opioid receptor, sigma 1 |
DOBUTAMINE |
Sigma1 |
72% |
2.518uM |
1.058uM |
View
|
| lymphocyte protein tyrosine kinase (mapped) |
DOBUTAMINE |
Protein Tyrosine Kinase, Lck |
72% |
5.519uM |
NoneNone |
View
|
| phosphodiesterase 4A, cAMP specific |
CELECOXIB |
Phosphodiesterase PDE4 |
68% |
9.26uM |
NoneNone |
View
|
| Sigma-2 Receptor |
AMITRIPTYLINE |
Sigma2 |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
AMOXAPINE |
Calcium Channel Type L, Benzothiazepine |
68% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2a |
AMIODARONE |
Imidazoline I2, Central |
68% |
7.826uM |
5.217uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
AMIODARONE |
Imidazoline I2, Central |
68% |
7.826uM |
5.217uM |
View
|
| Cytochrom P450-1A2 monooxygenase |
CHLORPROMAZINE |
CYP450-1A2 Inhibition |
68% |
NoneNone |
NoneNone |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
1-BENZYLIMIDAZOLE |
CYP450-2C9 Inhibition |
68% |
NoneNone |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
1-BENZYLIMIDAZOLE |
CYP450-2C9 Inhibition |
68% |
NoneNone |
NoneNone |
View
|
| A3 adenosine receptor |
NIFEDIPINE |
Adenosine A3 |
68% |
7.214uM |
4.078uM |
View
|
| mu-opioid receptor MOR |
CISAPRIDE |
Opiate mu |
68% |
NoneNone |
NoneNone |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
PAPAVERINE |
CYP450-3A4 Inhibition |
68% |
NoneNone |
NoneNone |
View
|
| Sigma-2 Receptor |
PERHEXILINE |
Sigma2 |
68% |
NoneNone |
NoneNone |
View
|
| cholinergic receptor, muscarinic 3 |
HEXACHLOROPHENE |
Muscarinic M3 |
68% |
NoneNone |
NoneNone |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
HEXACHLOROPHENE |
CYP450-3A4 Inhibition |
68% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-2C19 monooxygenase |
PROPAFENONE |
CYP450-2C19 Inhibition |
68% |
NoneNone |
NoneNone |
View
|
| matrix metallopeptidase 9 |
MESNA |
Protease, Matrix Metalloprotease-9 (MMP-9) |
68% |
NoneNone |
NoneNone |
View
|
| matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) |
MESNA |
Protease, Matrix Metalloprotease-9 (MMP-9) |
68% |
NoneNone |
NoneNone |
View
|
| dopamine receptor D4 |
1,3-DIPHENYLGUANIDINE |
Dopamine D4.2 |
68% |
NoneNone |
NoneNone |
View
|
| dopamine receptor 2 |
DESLORATADINE |
Dopamine D2L |
68% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
MONOBENZONE |
CYP450-2D6 Inhibition |
68% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
NALOXONAZINE |
CYP450-2D6 Inhibition |
68% |
NoneNone |
NoneNone |
View
|
| arachidonate 15-lipoxygenase, second type |
RIFAPENTINE |
Lipoxygenase 15-LO |
68% |
NoneNone |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
RIFAPENTINE |
Lipoxygenase 15-LO |
68% |
NoneNone |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
RIFAPENTINE |
Lipoxygenase 15-LO |
68% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2a |
LEAD(IV) ACETATE |
Adrenergic alpha2A |
68% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type X, alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage gated, type VIII, alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type IV, alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| histamine receptor H 2 |
QUINACRINE |
Histamine H2 |
72% |
3.535uM |
3.476uM |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
IMIQUIMOD |
Adrenergic alpha1D |
72% |
2.621uM |
1.288uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
BOPINDOLOL |
Calcium Channel Type L, Benzothiazepine |
72% |
2.805uM |
2.493uM |
View
|
| Cytochrom P450-2C19 monooxygenase |
NIMODIPINE |
CYP450-2C19 Inhibition |
72% |
4uM |
NoneNone |
View
|
| dopamine receptor D1A |
OXICONAZOLE |
Dopamine D1 |
72% |
4.1361uM |
2.068uM |
View
|
| opioid receptor, delta 1 |
OXICONAZOLE |
Opiate delta |
72% |
5.3081uM |
1.8712uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
OXYMETAZOLINE |
Serotonin 5-HT2B |
72% |
3.056uM |
1.945uM |
View
|
| ATPase, Na+/K+ transporting, alpha 4 polypeptide |
SODIUM ORTHOVANADATE |
ATPase, Na+/K+ |
72% |
1.853uM |
NoneNone |
View
|